{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:59:50Z","timestamp":1792799990142,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The effect of elevated luteinizing hormone (LH) on the clinical outcomes of ovulation induction (OI) in infertile anovulatory patients with polycystic ovary syndrome (PCOS) remains controversial. This retrospective study included PCOS patients undergoing intrauterine insemination (IUI) following letrozole (LE) stimulation without OC pretreatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A retrospective cohort analysis was conducted in a single, academic ART center from January 2013 to May 2019. In total, 835 IUI cycles of PCOS patients treated with letrozole were collected for the analysis. Cohorts were separated based on the level of basal LH (bLH) and LH level after letrozole administration (LH<jats:sub>le<\/jats:sub>) during OI. OI response and reproductive outcomes were evaluated for each cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No adverse effects of dysregulated levels of either bLH or LH<jats:sub>le<\/jats:sub> on ovulation rate or reproductive outcomes were observed. Furthermore, the cohort of individuals with normal bLH and high LH<jats:sub>le<\/jats:sub> levels, exclusive of LH surge, exhibited significantly higher rates of clinical pregnancy (30.3% vs. 17.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002) and live birth (24.2% vs. 15.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.024) than those with normal bLH and normal LH<jats:sub>le.<\/jats:sub><\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results indicated that high LH levels in PCOS are not solid evidence of poor prognosis of letrozole-induced ovulation, while elevated LH<jats:sub>le<\/jats:sub> may be a prospective predictor for better OI outcomes. It seems that preinhibition of LH secretion is not needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1113840","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T05:09:24Z","timestamp":1681794564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Role of luteinizing hormone elevation in outcomes of ovulation induction with letrozole for polycystic ovary syndrome"],"prefix":"10.3389","volume":"10","author":[{"given":"Wenyan","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria","volume":"27","author":"Yildiz","year":"2012","journal-title":"Hum Reprod"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-14-0253","article-title":"The polycystic ovary syndrome: a position statement from the European Society of Endocrinology","volume":"171","author":"Conway","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.fertnstert.2007.09.041","article-title":"Consensus on infertility treatment related to polycystic ovary syndrome","volume":"89","year":"2008","journal-title":"Fertil Steril."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/s0015-0282(97)80068-4","article-title":"Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome","volume":"67","author":"Van Santbrink","year":"1997","journal-title":"Fertil Steril"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/00006254-200211000-00022","article-title":"New approach to polycystic ovary syndrome and other forms of anovulatory infertility","volume":"57","author":"Laven","year":"2002","journal-title":"Obstet Gynecol Surv"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0974-1208.82351","article-title":"Luteinizing hormone and its dilemma in ovulation induction","volume":"4","author":"Kumar","year":"2011","journal-title":"J Hum Reprod Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/oxfordjournals.humrep.a138174","article-title":"Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin","volume":"8","author":"Balen","year":"1993","journal-title":"Hum Reprod"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/s0015-0282(00)01701-5","article-title":"A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome","volume":"75","author":"Gordon","year":"2001","journal-title":"Fertil Steril"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/humrep\/17.4.1017","article-title":"Follicular fluid markers of oocyte developmental potential","volume":"17","author":"Mendoza","year":"2002","journal-title":"Hum Reprod"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1210\/jcem.85.2.6356","article-title":"Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility","volume":"85","author":"Imani","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1056\/NEJMoa1313517","article-title":"Letrozole versus clomiphene for infertility in the polycystic ovary syndrome","volume":"371","author":"Legro","year":"2014","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0536.2007.01304.x","article-title":"Oral contraceptives: mechanism of action, dosing, safety, and efficacy","volume":"81","author":"Sondheimer","year":"2008","journal-title":"Cutis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1210\/jc.2014-3196","article-title":"Approach to the patient: contraception in women with polycystic ovary syndrome","volume":"100","author":"Yildiz","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3109\/09513590.2013.831834","article-title":"Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study","volume":"29","author":"Di Carlo","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"ref18","year":"2010"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0015-0282(00)01783-0","article-title":"Effect of the total motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization","volume":"75","author":"Van Voorhis","year":"2001","journal-title":"Fertil Steril"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40738-020-00092-1","article-title":"Predictive factors for intrauterine insemination outcomes: a review","volume":"6","author":"Starosta","year":"2020","journal-title":"Fertil Res Pract"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/0140-6736(90)92765-A","article-title":"Hypersecretion of luteinising hormone, infertility, and miscarriage","volume":"336","author":"Regan","year":"1990","journal-title":"Lancet"},{"key":"ref22","first-page":"1","article-title":"National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome (PCOS)","volume":"1","author":"Johnson","year":"2012","journal-title":"NIH EbMW Report"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1210\/jc.2010-1123","article-title":"Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism","volume":"95","author":"Legro","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejogrb.2017.09.023","article-title":"Ovulation induction and controlled ovarian stimulation using letrozole gonadotropin combination: a single center retrospective cohort study","volume":"218","author":"Arya","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00404-013-2780-5","article-title":"Letrozole usage adjuvant to gonadotropins for ovulation induction for patients with clomiphene citrate failure","volume":"288","author":"Ozdemir","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0015-0282(16)36665-1","article-title":"The myth of oral contraceptives in the treatment of infertility","volume":"19","author":"Whitelaw","year":"1968","journal-title":"Fertil Steril"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1023\/A:1009410416638","article-title":"The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment","volume":"17","author":"Genazzani","year":"2000","journal-title":"J Assist Reprod Genet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1067\/mob.2003.459","article-title":"A randomized clinical trial of treatment of clomiphene citrate-resistant anovulation with the use of oral contraceptive pill suppression and repeat clomiphene citrate treatment","volume":"188","author":"Branigan","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"813188","DOI":"10.3389\/fendo.2022.1036243","article-title":"A randomized cohort study: is it worth the time to receive antiandrogenic Pretreatment before ovulation induction for women with polycystic ovary syndrome?","volume":"13","author":"Chen","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S0015-0282(16)53282-8","article-title":"Gonadotropin suppression with oral contraceptives before in vitro fertilization","volume":"53","author":"Gonen","year":"1990","journal-title":"Fertil Steril"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/humrep\/deh369","article-title":"Recombinant human LH supplementation during GnRH antagonist administration in IVF\/ICSI cycles: a prospective randomized study","volume":"19","author":"C\u00e9drin-Durnerin","year":"2004","journal-title":"Hum Reprod"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/humrep\/dei302","article-title":"A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients","volume":"21","author":"Rombauts","year":"2006","journal-title":"Hum Reprod"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1023\/A:1009462004650","article-title":"Does pretreatment with progestogen or oral contraceptive pills in low responders followed by the GnRHa flare protocol improve the outcome of IVF-ET?","volume":"17","author":"Al-Mizyen","year":"2000","journal-title":"J Assist Reprod Genet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1093\/humrep\/12.11.2359","article-title":"Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients","volume":"12","author":"Damario","year":"1997","journal-title":"Hum Reprod"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/humrep\/dew325","article-title":"Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome","volume":"32","author":"Wei","year":"2017","journal-title":"Hum Reprod"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1210\/jc.2015-2778","article-title":"Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome","volume":"100","author":"Legro","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7827-11-54","article-title":"First intention IVF protocol for polycystic ovaries: does oral contraceptive pill pretreatment influence COH outcome?","volume":"11","author":"Decanter","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.fertnstert.2007.05.035","article-title":"Pretreatment with oral contraceptives in infertile anovulatory patients with polycystic ovary syndrome who receive gonadotropins for controlled ovarian stimulation","volume":"89","author":"Palomba","year":"2008","journal-title":"Fertil Steril"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1113840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T05:09:29Z","timestamp":1681794569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1113840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":39,"alternative-id":["10.3389\/fmed.2023.1113840"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1113840","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"article-number":"1113840"}}